NCT03420963 - Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2018

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2027

Conditions

Recurrent Cutaneous MelanomaRecurrent Lip and Oral Cavity CarcinomaRecurrent Malignant Endocrine NeoplasmRecurrent Malignant Female Reproductive System NeoplasmRecurrent Malignant Male Reproductive System NeoplasmRecurrent Malignant MesotheliomaRecurrent Malignant Neoplasm of Multiple Primary SitesRecurrent Malignant Oral NeoplasmRecurrent Malignant Pharyngeal NeoplasmRecurrent Malignant Skin NeoplasmRecurrent Malignant Soft Tissue NeoplasmRecurrent Malignant Solid NeoplasmRecurrent Malignant Thyroid Gland NeoplasmRecurrent Malignant Urinary System NeoplasmRefractory Cutaneous MelanomaRefractory Malignant Bone NeoplasmRefractory Malignant Endocrine NeoplasmRefractory Malignant Female Reproductive System NeoplasmRefractory Malignant Male Reproductive System NeoplasmRefractory Malignant MesotheliomaRefractory Malignant Neoplasm of Multiple Primary SitesRefractory Malignant Oral NeoplasmRefractory Malignant Pharyngeal NeoplasmRefractory Malignant Skin NeoplasmRefractory Malignant Soft Tissue NeoplasmRefractory Malignant Solid NeoplasmRefractory Malignant Thyroid Gland NeoplasmRefractory Malignant Urinary System Neoplasm

Interventions

BIOLOGICAL

Cord Blood-derived Expanded Allogeneic Natural Killer Cells

Given IV

DRUG

Cyclophosphamide

Given IV

DRUG

Etoposide

Given IV

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER